Efficacy and safety of apixaban compared to warfarin for prevention of stroke and systemic embolism
Sunday, August 28, 2011 - 10:30
in Health & Medicine
A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, apixaban results in substantially less bleeding, and also results in lower mortality. The benefits of apixaban are consistent irrespective of how well warfarin is used at different centers, as measure by "time in therapeutic range."